ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.77
-1.09%
US Tech 100
20,778.00
-0.69%
S&P 500
6,040.53
-0.50%
US Dollar vs CAD
1.45415
0.01%
Bitcoin
97,576.12
-3.06%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Biogen Inc (0R1B)

  7. Biogen Inc (0R1B) News

0R1B

Biogen (0R1B)

Biogen Inc
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0R1B
DateTimeSourceHeadlineSymbolCompany
01/31/20255:30AMUK RegulatoryUpdate on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European UnionLSE:0R1BBiogen Inc
01/26/20255:33PMUK RegulatoryFDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s DiseaseLSE:0R1BBiogen Inc
01/23/20256:30AMUK RegulatoryFDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMALSE:0R1BBiogen Inc
01/13/20256:05PMUK RegulatoryFDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s DiseaseLSE:0R1BBiogen Inc
11/19/202412:00AMUK RegulatoryDapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease ActivityLSE:0R1BBiogen Inc
11/14/202410:23AMUK RegulatoryEisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s DiseaseLSE:0R1BBiogen Inc
10/30/20246:30PMUK RegulatoryEisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) ConferenceLSE:0R1BBiogen Inc
10/29/20245:00PMUK RegulatoryBiogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological DiseasesLSE:0R1BBiogen Inc
10/29/20247:00AMUK RegulatoryBiogen Appoints Daniel Quirk, MD, as Chief Medical OfficerLSE:0R1BBiogen Inc
10/28/20247:30AMUK RegulatoryMichael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025LSE:0R1BBiogen Inc
10/26/20247:15PMUK RegulatoryBiogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024LSE:0R1BBiogen Inc
10/24/20246:30AMUK RegulatoryBiogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual ConferenceLSE:0R1BBiogen Inc
10/22/20246:30AMUK RegulatoryBiogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024LSE:0R1BBiogen Inc
10/09/20246:30AMUK RegulatoryBiogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant RecipientsLSE:0R1BBiogen Inc
10/08/20246:30AMUK RegulatoryNew Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMALSE:0R1BBiogen Inc
09/24/202412:00AMUK RegulatoryUCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024LSE:0R1BBiogen Inc
09/12/20246:30AMUK RegulatoryBiogen Board Appoints Two New Independent DirectorsLSE:0R1BBiogen Inc
09/04/20246:30AMUK RegulatoryBiogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMALSE:0R1BBiogen Inc
07/30/20244:15PMUK RegulatoryNew Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAICLSE:0R1BBiogen Inc
07/30/20246:30AMUK RegulatoryBiogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s DiseaseLSE:0R1BBiogen Inc
07/26/20246:20AMUK RegulatoryUpdate on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European UnionLSE:0R1BBiogen Inc
03/06/20246:30AMUK RegulatoryNew Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene TherapyLSE:0R1BBiogen Inc
03/04/20243:15PMUK RegulatoryBiogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual MeetingLSE:0R1BBiogen Inc
02/23/20246:00AMUK RegulatoryBiogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMPLSE:0R1BBiogen Inc
02/12/20243:06PMUK RegulatoryBiogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s AtaxiaLSE:0R1BBiogen Inc
01/31/20246:30AMUK RegulatoryBiogen to Realign Resources for Alzheimer's Disease FranchiseLSE:0R1BBiogen Inc
08/06/202311:07AMAlliance NewsAlliance NewsCORRECT: Biogens, Sage Therapeutics postpartum depression drug okayedLSE:0R1BBiogen Inc
08/06/20238:17AMAlliance NewsAlliance NewsBiogens, Sage Therapeutics postpartum depression treatment approvedLSE:0R1BBiogen Inc
06/09/20236:12AMAlliance NewsAlliance News*Nasdaq halts trading of Biogen stockLSE:0R1BBiogen Inc
01/13/20208:28AMAlliance NewsAlliance NewsPfizer Could Net USD635 Million As Biogen Acquires Alzheimer's DrugLSE:0R1BBiogen Inc
 Showing the most relevant articles for your search:LSE:0R1B

Your Recent History

COIN
XRPUSD
Ripple
COIN
BTCUSD
Bitcoin
USOTC
NWBO
Northwest Biotherapeutics (QB)
NASDAQ
LWLG
Lightwave Logic
USOTC
BIEL
Bioelectronics (PK)
USOTC
RDGL
Vivos (QB)
NASDAQ
COOP
Mr Cooper
USOTC
NBRI
North Bay Resources (PK)
NASDAQ
AMRN
Amarin
NASDAQ
NVDA
NVIDIA
USOTC
PSRU
Valiant Eagle (PK)
USOTC
FNMA
Fannie Mae (QB)
USOTC
ELTP
Elite Pharmaceuticals (QB)
NASDAQ
AVXL
Anavex Life Sciences
USOTC
HMBL
HUMBL (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads